The Latest Breaking News from Moderna

Tesla stock was the top S&P 500 gainer on Tuesday as its Berlin-area factory began Model Y deliveries.

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments. 

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine.  The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases.

The FDA will discuss Covid booster shots from Pfizer and Moderna next month — possibly giving vaccine stocks another chance to shine.

LOS ANGELES — Coronavirus cases are on the upswing worldwide, prompting some officials to warn that California could see increases this spring because of the omicron subvariant BA.2 even though cases so far have been modest.

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Buying plunging S&P 500 stocks on a dip is not a profitable long-term winning strategy — and usually a good way to lose money.

Moderna asked the FDA to authorize its Covid booster for all adults — a much wider request than Pfizer's — and Moderna stock popped Friday.